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Endothelin is a potent vasoactive peptide occurring in three isotypes, ET-1, ET-2, and ET-3. Through its two main receptors,
endothelin A and endothelin B, it is responsible for a variety of physiological functions, primarily blood ﬂow control. Recent
evidence from both human and animal models shows involvement of endothelin in diabetes, retinal circulation, and optic
neuropathies. Increased circulating levels of endothelin-1 (ET-1) have been found in patients with diabetes, and a positive
correlation between plasma ET-1 levels and microangiopathy in patients with type-2 diabetes has been demonstrated. In addition
toitsdirectvasoconstrictoreﬀects,enhancedlevelsofET-1maycontributetoendothelialdysfunctionthroughinhibitoryeﬀectson
nitric oxide (NO) production. Experimental studies have shown that chronic ET-1 administration to the optic nerve immediately
behindtheglobe causes neuronal damage, activation of astrocytes, themajor glial cellin the anterioroptic nerve,and upregulation
of endothelin B receptors. This paper outlines the ubiquitous role of endothelin and its potential involvement in ophthalmology.
1.Introduction
Endothelin 1 (ET-1) is a potent vasoconstrictor [1]p e p t i d e
that is also expressed in neurons [2]. The peptide comprises
21 amino-acids with two intrachain disulﬁde linkages and
was ﬁrst isolated from the culture supernatant of porcine
aorta endothelium cells in 1988 [1]. Endothelin derives
from “big endothelin” a prepropeptide that is cleaved by
endothelin-convertingenzymestoproducematureendothe-
lin [3].
Since its identiﬁcation, endothelin has attracted intensive
interdisciplinavy interest because of its unique proﬁle as
an endothelium-derived vasoactive factor with a powerful
and characteristically long-lasting vasopressor activity. Thus,
whereas cellular mechanism of endothelin action appear
to be similar to classic vasoconstrictor substances such as
angiotensin II and norepinephrine, the slow time course of
the regulatory mechanisms of its biosynthesis and secretion
resembles more that of inﬂammatory cytokines. These char-
acteristics make this family of small peptides unique within
the realm of intercellular mediators with cardiovascular
relevance [4].
Endothelin is expressed in three isoforms called ET-1,
ET-2, and ET-3, with slightly diﬀerent amino-acid sequences
and diﬀerent distribution in various tissues. Accordingly,
three diﬀerent genes encoding the endothelins have been
identiﬁed in the human, rat, and pig genome [5]. Further-
more, three ET receptor subtypes called ETA,E T B and ETC
have been described.
The presence of ET-1 has been demonstrated in the
human brain, pituitary gland [6], spinal cord [2], lung [7],
rat bladder [6], rat kidney, feline intestinal tissue [7]a n d
human and rat eye [8]. In rabbit, ET-1 has also been found
in the tear glands [9]. ET-1 is present in the aqueous humour
at concentrations several times higher than in plasma,
presumably because it is secreted by the ciliary epithelium
a n dn o td e r i v e df r o mp l a s m a[ 10]. ET-3 is less ubiquitous
and is found in the iris, ciliary body, and retina in some
species. The presence of ET-2 in the eye has not been studied
extensively. However, in the context of a possible role for this
isoform in the eye pathophysiology Murata and coworkers
foundnoevidenceofET-2geneexpressionintheretina[11].
The vascular endothelium modulates local vascular tone
byreleasingrelaxingfactorssuchasnitricoxide,prostacyclin,
and endothelium-derived hyperpolarizing factors as well
as the potent vasoconstrictor peptide endothelin-1 [12].
Although this local regulatory system can be found in nearly
all vertebrates, a great heterogeneity exists between diﬀerent2 Journal of Ophthalmology
species, particularly in the various chemical and hormonal
agonists that can stimulate the release of these endothelium-
derived factors and between large and small vessels and
diﬀerent vascular beds [13].
Haeﬂiger and coworkers [14] demonstrated the presence
ofboththeendothelium-derivedrelaxingfactor,nitricoxide,
and the vasoconstrictor peptide endothelin in the human
ophthalmic artery. These authors found that in human
ophthalmic arteries, the endothelial L-arginine/nitric oxide
pathway is active under basal conditions and is further
stimulated by bradykinin, acetylcholine, and histamine,
whereas ET1 has a potent vasoconstrictor eﬀect. The potency
of these responses suggests an important physiological role
for endothelium-derived vasoactive substances in the regu-
lation of the human ophthalmic circulation. Furthermore, a
dysfunction of these endothelial mechanisms, which occurs
in diabetes and hypertension (at least in peripheral arteries)
may play an important role in the pathophysiology of
ophthalmic complications [15].
In addition, in a subpopulation of patients with glau-
coma presenting ocular vasospasms, endothelial dysfunction
may represent the underlying cause or at least contribute to
alterations in ophthalmic blood ﬂow [16].
Vascular ET-1 is synthesized primarily in the endothe-
lium, although it can also be produced in vascular smooth
muscle cells, macrophages, leukocytes, cardiomyocytes, and
ﬁbroblasts [17].
Inthekidney,tubularepithelialcells,mesangialcells,and
podocytes are capable of ET-1 release [18].
Several mechanism are involved in the clearance of ET-1
from plasma, including endocytosis in the lungs, enzymatic
degradation, degradation of the endothelinB receptor ligand
complex, and enzymatic processes in the kidney and liver
[19, 20].
ET-1 is the most potent vasoconstrictive substance kno-
wn, more potent than angiotensin II [1]. It has been
shown to be highly concentrated in human atherosclerotic
plaques with coronary vasospasm [21] and is also present
in human plasma [22]. In addition, ET-1 mediates a wide
variety of biological activities, including contraction of non
vascular smooth muscle [23], thus leading, for example,
to bronchoconstriction [24]. ET-1 also stimulates mitotic
activity of rat vascular smooth muscle cells [25] and is
thought to act as neuropeptide [2].
Endothelins are also associated with neuronal apopto-
tosis in the central nervous system. Exposure of retinal
ganglion cells (RGCs) or RGC-5 cells, a transformed cell
line, to ET-1 causes apoptic cell death. In addition, it was
demonstrated that ET-1 enhances the glutamate-induced
deathofculturedretinalneurons.FurthermoreSyedandcol-
leagues[26]showedthatanonselectiveETantagonistisneu-
roprotective in the rat retina during ischemia/reperfusion.
These ﬁndings indicate that ET-1 is involved in the cell
death signalling pathway(s) in retinal neurons. Interactions
between ET-1 and nitric oxide synthase (NOS) have been
well documented. For example stimulation of ETB receptors
leads to vasodilation through the formation of nitric oxide
(NO), and an intravitreal injection of ET-1 enhances NO
productionintheopticnerveofrabbits.NOSisstronglycou-
pled to the generation of superoxide through the uncoupling
of NOS. NO can aﬀect mitochondrial function and increase
the formation of superoxide by mitochondria. Under these
conditions, NO is inactivated by superoxide anion and
changed into highly toxic peroxynitrite. Superoxide also
causes neuronal apoptosis, and an inhibition of its formation
has neuroprotective eﬀects. Reactive oxygen species (ROS),
forexample,nitricoxide,superoxide,andperoxynitrite,con-
tribute to neurodegenerative diseases including Parkinson
disease and amyotrophic lateral sclerosis.
In a recent study, Oku and coworkers also demonstrated
that ET-1 causes death of retinal neurons through activation
of NOS and production of superoxide anion [27].
Although ET-1 appears to act mainly as a local para-
crine/autocrinepeptide,circulatinglevelsofendothelinseem
also to have biological signiﬁcance, especially in pathological
states of increased serum concentration.
So far there has been no comprehensive report on the
multifunctional role of ET-1 in the human eye. Therefore,
the present paper is speciﬁcally addressed to illustrate ET-1
functions in the healthy and diseased eye.
2.ET-1 andHumanCorneal Epithelium
ET-1 was found in the human corneal epithelium [28].
Interestingly, ET-1 has also been demonstrated in rabbit tear
ﬂuid [13]. Furthermore, in the rabbit ET-1 is able to induce
proliferation of cultured corneal epithelial cells [29]a n dt o
promote corneal wound healing. Bek and McMillen [30]
found that ET-1 is angiogenic in the rat cornea and this
eﬀectappears to be direct and dependent on activation of the
ETA receptor. Likewise, ET-1 might be involved in regulating
growth of human corneal epithelial cells, which is important
for the continuous renewal of cornea and recovery from
corneal trauma and keratoplasty.
3.ET-1andRetinalCirculation
Ithasbeendemonstratedthatendothelinscanmodulatereti-
nal pericyte contractility and, hence, retinal hemodynamics.
Because of the potential importance of pericytes in main-
taining normal retinal physiology and the involvement of
pericyte dysfunction in diseases such as diabetes and diabetic
retinopathy, studies were performed to characterize the local
eﬀects of endothelin on retinal hemodinamics in the rat eye.
The retinal hemodynamic changes in response to intravitreal
injections of endothelin were quantitated in diabetic and
nondiabetic rats using a retinal video ﬂuorescein angiog-
raphy system. Bursell and coworkers [31] demonstrated
that the retinal circulation responds directly, in a dose-
dependent manner, to ET-1 injection. The vasoconstrictor
activity appears to be associated primarily with the retinal
arteries, whose diameter is reduced by 17% 15 minutes after
10−7 M ET-1 injection, compared to baseline preinfusion
diameters. Correspondingly, the veins demonstrated a non
signiﬁcant (6%) reduction in diameter that was at least three
times smaller than the arterial response. In the diabetic rat,
the retinal response to ET-1 injection was approximately 10
timessmaller(P = .01)thanthatobservedinthenondiabeticJournal of Ophthalmology 3
rats. This reduction in the physiological response in diabetic
animals parallels that observed in retinal pericytes cultured
under high-glucose conditions and suggests that retinal
pericyte function is impaired at early stages in diabetes. It
has also been shown that glucose can cause an enhanced
secretion of endothelin from cultured endothelial cells and
that retinal pericytes demonstrate prolonged desensitization
to further stimulation by ET-1 after the ﬁrst application
of endothelin. The ﬁndings suggest that the blunted ET-1
responseobservedindiabeticratsresultsfromET-1secretion
enhanced by glucose, endothelin receptor desensitization, or
both. Although this phenomenon is still under investigation
the fact that retinal blood ﬂow is decreased at an early
stage in diabetes suggests that increased ET-1 secretion and
the resultant vasoconstriction at the microcirculatory level,
potentially mediated by the retinal pericytes, contributes to
thedecreasedretinalbloodﬂowobservedindiabeticanimals.
This may represent one of the molecular mechanisms related
to the subsequent development of microvascular disease and
diabetic retinopathy.
4.ET-1andDiabeticRetinopathy
Several studies support the hypothesis that endothelial
dysfunction anticipates type 2 diabetes, indicating that
vascular endothelial dysfunction may precede insulin resis-
tance, although the features of insulin resistance syndrome
include factors that have negative eﬀects on endothelial
function. Impaired endothelial-dependent and independent
microvascular reactivity has also been demonstrated in
healthy subjects with risk factors for type 2 diabetes.
One important feature of endothelial dysfunction is an
increased production and biological activity of the potent
vasoconstrictorandproinﬂammatorypeptideET-1.Elevated
levels of ET-1 are found in patients with type 2 diabetes,
[33] (see Figure 1), and ET-1-induced reduction in insulin
sensitivity may take part in the development of the metabolic
syndrome. Therefore, in diabetes mellitus the disturbance in
ET-1 production from vascular endothelium represents an
early phenomenon rather than the result of advanced stage
of the disease.
Furthermore,ET-1maycontributetothedevelopmentof
endothelial dysfunction,andconsequentlyinsulinresistance,
by increasing the production of reactive oxygen species,
mainly superoxide anion, in the vasculature. This is mainly
dependent upon activation of NADPH oxidase protein
expression and activity. ET-1 levels in tissues are closely
linked with reactive oxygen species (ROS) to serve as pro-
inﬂammatory factors, and ROS are considered important
factors in mechanisms underlying diabetic complications
and cardiovascular derangement [34].
Su et al. [35] investigated at the molecular level the
eﬀects of total triterpene acids (TTAs) from Fructus Corni
on early diabetic complications and whether the novel
endothelin receptor antagonist CPU0213 could reverse these
pathological changes via suppression of ET and inducible
nitric oxide synthase (iNOS) in early diabetic retinopathy.
Furthermore, they compared the eﬀects of TTAs with those
produced by blocking the receptors of advanced glycation
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Figure 1: The plasma immunoreactive-endothelin concentrations
were found to be greatly raised in the patients with diabetes
(1,880 +/− 120fmol/l, mean +/− SEM) compared with the healthy
subjects (540 +/− 50fmol/l, P less than .005). Figure adapted from
Takahashi et al. [32].
end-products (RAGE) and iNOS by amino guanidine an
advanced glycation end-products antagonist. They found
that activated RAGE may accelerate the biosynthesis and
release of inﬂammatory factors, including ET-1, ROS and
iNOS. Endothelin-1 and ROS interaction results in a vicious
cycle leading to mutual enhancement of vascular and cellular
eﬀects that converge to represent aetiological factors that
damage macromolecules in tissues. This process may involve
n u c l e a rf a c t o r - ( N F - )k Ba n dt u m o rn e c r o s i sf a c t o r - α.
The extracellular matrix of the retina, which accumulates
in retinopathy, is composed of mainly ﬁbronectin, which
undergoes alternative splicing to produce embryonic iso-
forms of fetal ﬁbronectin, and increased levels of ﬁbronectin
contribute to retinopathy [36].
Fibronectin and its isomers are involved in endothelial
cell proliferation and the increase in the extracellular matrix
can be prevented by endothelin receptor antagonism by
bosentan [37].
Diabetes produces increased microvascular permeability
along with increased vascular endothelial growth factor
(VEGF) mRNA expression, resulting in the deposition of
hard exudates in the retina, where VEGF and ET-1 are
known to interact. Thus, upregulation of the ETA receptor
can be considered a biomarker for the development of early
retinopathy in diabetes. The endothelin receptor antagonist
CPU0213 does not substantially aﬀect fasting serum glucose,
but it improves the vascular and retinal complications of
diabetic rats, in agreement with its amelioration of diabetic
cardiomopathy. Furthermore, TTAs reverse the abnormal
upregulation of the ET system in the vasculature and the
abnormal expression of the ETA receptor and iNOS mRNA
in retinal tissues. Thus, TTAs are likely to exert antioxidative
and antiproliferative eﬀects on diabetic retinopathy and
vasculopathy by suppression of the protein kinase C (PKC)
and mitogen-activated protein kinase (MAPK) pathways
and, indirectly, by suppressing the overexpression of ppET-
1, ECE, ETA receptor and iNOS mRNA. Thus, the eﬀects of
TTAs resemble those of endothelin receptor antagonists and
may be superior to amino guanidine in alleviating diabetic
complications such as retinopathy and vasculpathy.4 Journal of Ophthalmology
Compromised vasorelaxation reduces blood perfusion in
the retina, leading to upregulation of the ET system and to
higher levels of ET-1 in the vasculature. This will further
impair relaxation of vasculature smooth muscle because ET-
1 is a very potent vasoconstrictor. More importantly, ET-
1 produces proliferation of the vascular smooth muscle,
increasing the thickness in the vasculature, reducing lumen
size, increasing its thickness of the basement membran and
thus decreasing permeability in the retina. The proliferative
actions of ET-1 are likely to increase extracellular matrix
and stimulate ﬁbrosis in the retina, eventually producing
proliferative retinopathy. Golubovic-Arsovska [38]f o u n d
that upregulation of ETA receptor is related, at least in
part, to the development of preproliferative and proliferative
retinopathy in clinical settings and correlates with the
appearance of maculopathy and macular edema.
The overexpression of ET-1 serves as a key biomarker for
endothelial dysfunction that is likely related to superoxide
generation and activated phosphatidyl 3-kinase activity [39].
Makino et al. [40] suggested that an increase in the
basal and α-adrenoceptor agonist-induced release of ET-1
in diabetes can be attributed to an overexpression of the
mRNA for the ppET-1. An excess of ET-1 binding to the
ETA receptorstimulatesthePKCandMAPKpathways,which
leads to phenotypic abnormalities in the genes encoding for
the ppET-1, iNOS, proliferation of matrix formation, and
vascular smooth muscle [41].
The molecular mechanisms of NOS regulation in hyper-
glycemia are not fully known, but recent studies point to a
decisive role of an activated PKC pathway. Hyperglycaemia
markedly activates the BII isoform of PKC in endothelial
cells by promoting de novo synthesis of diacylglycerol and
increasing mitochondrial superoxide production [42].
Diabetic retinopathy is a potentially sight-threatening
complication that develops in nearly all patients with
diabetes. Ocular tissues, for example, vascular and extravas-
cular sites in the retina are sources of ET-1, and ET-1
contributes to abnormal retinal hemodinamics in diabetic
retinopathy. Results from several studies on streptozocin-
induced diabetes in rats have suggested a role of ET-1
in the pathogenesis of diabetic retinopathy. An interaction
between ET-1 and VEGF has also been reported, and
preliminary positive results of treatment with endothelin
receptor blockers have raised interest in these substances as
potentiallytherapeuticagents.Mostofthestudiesontherole
of ET-1 in the pathogenesis of diabetic retinopathy and on
the importance of endothelin blockers in the treatment of
this serious complication have been done in animal models.
Nevertheless, they provide suﬃc i e n te v i d e n c et h a ts t r o n g l y
links ET-1 to the pathogenesis of diabetic retinopathy.
5.ET-1andRetinitisPigmentosa
Retinitis pigmentosa (RP) is a group of clinically and genet-
ically heterogeneous retinal degenerations characterized by
chronic progressive loss of rod and cone photoreceptor
function [44]. The damage is actually explained with
an invalid gene product or protein causing a metabolic
wrong step in the phototransduction process. Diﬀerent
inheritance patterns of tapetoretinal degenerations were
described:autosomaldominant,recessiveandX-linked,allof
them associated with point mutations and intragenic micro
deletionsaswellasothermoleculardefectswithinoverforty-
ﬁve diﬀerent RP and loci [45]. Hemodynamic studies have
demonstratedthatRPisassociatedwithareductioninretinal
andchoroidalbloodﬂow.Retinalhemodynamicimpairment
is also present in early stages of RP and among the various
hypotheses advanced on the causative factors involved in this
impairment the ET-1-mediated vasoconstriction is a likely
candidate.
ET-1 has been shown to be expressed in the retina,
including the photoreceptors, the inner plexiform layer and
theganglioncelllayer[46].Thechoroid,thevascularsmooth
muscle in retinal blood vessels and choriocapillaris have also
been shown to contain receptors for ET-1.
Secretion of ET-1 by the retinal pigment epithelium
(RPE) could target receptors on the apical (photoreceptors)
or basal (choroid) sides. Activation of ET receptors in the
retinal or choroidal vasculature may be important in regu-
lating blood ﬂow at this region. Haemodynamic studies have
demonstratedthatRPisassociatedwithareductionofretinal
and choroidal blood ﬂow [47]e v e ni ne a r l ys t a g e so fR P .
These vascular abnormalities might be correlated with
the increased plasma ET-1 concentration that was found in
two studies on RP patients [43, 48]( Figure 2). Although
thesedatarequirefurtherinvestigationinalargerpopulation
of patients, these studies open the possibility that antien-
dothelin drugs could result therapeutically useful in RP
administered either alone or in association with treatments
directed to improving tissue oxygenation such as hyperbaric
oxygen therapy [49].
6. Endothelin-1 andthe OpticNerve Head
Open angle glaucoma is the most common optic neuropathy
causingretinalganglioncell(RGC)somaandaxonloss,optic
nerve head (ONH) structural loss, and visual ﬁeld damage.
Elevated intraocular pressure (IOP) is the most potent risk
factor known for causing glaucomatous damage. Decades of
experimental and clinical research consolidated the notion
that lowering IOP has a favourable impact in the majority of
patientswithglaucoma.Thishasbeenconﬁrmedinrandom-
ized clinical trials that included untreated control arms [53].
How IOP can lead to structural damage and produce clinical
glaucoma is not fully understood. Much evidence points to
theONH,consistingofRGCaxons,bloodvessels,connective
tissues and glia, as the primary site of damage in glaucoma
[54].ItislikelythatthemicroenvironmentintheONHreacts
to stressors such as IOP and other potential IOP-dependent
or IOP-independent factors, such as ischemia, to ultimately
cause RGC axonal damage (Figure 3). The potential of
endogenous vasoconstrictors to cause ischemic insult in
the ONH was proposed many years ago and endothelin
represents one vasoconstrictor agent with a possible role in
glaucoma and other neurodegenerative diseases (Figure 3).
An impairment of the anterior optic nerve microcirculation
has been suspected to contribute and/or to be a causal factor
in a variety of optic neuropathies. Thus, endothelins thatJournal of Ophthalmology 5
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Figure 2: (a) Scatter plot of ET-1 plasma values in patients with retinitis pigmentosa (RP), syndromic retinitis pigmentosa (syndromic RP),
and healthy subjects (HS). (b) Mean (M ± SD) plasma ET-1 levels in patients with RP, syndromic RP, and HS. Figure adapted from Vingolo
et al. [43].
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Figure 3: Potential mechanism of endothelin (ET) and ET receptor-mediated actions causing retinal ganglion cell (RGC) loss. Optic nerve
astrocytes may become activated via ET actions, leading to extracellular matrix (ECM) changes in the optic nerve head and eventual RGC
loss. Figure adapted from Chauhan BC [50].
produce dose-dependent vasoconstriction in various vascu-
larbeds,includingtheanterioropticnervemicrovasculature,
become likely candidates able to produce neural damage.
Indeed, these peptides have been shown to produce localized
vasoconstriction when injected directly into perivascular
cerebral tissues in vivo and to result in regional ischemic
damage of the brain nervous tissue [55].
Increased plasma ET-1 levels have been described in
normal tension glaucoma patients, although this ﬁnding was
not conﬁrmed in every study dealing with normal tension
glaucoma patients or in studies with high tension glaucoma
patients. On the other hand, the fact that aqueous ET-1
concentration is increased in primary open-angle glaucoma
and in animal models of glaucoma underscores the possible
contribution of endothelin to the pathogenesis of primary
open angle glaucoma. Furthermore, chronic administration
of ET-1 has been shown to produce an optic neuropathy
similar to glaucoma. In the rabbit animal model of glaucoma
Org¨ ul et al. [51] assessed optic nerve blood ﬂow after local
administration of endothelin-1 in vivo. In addition, the
eﬀect of optic nerve ischemia was monitored by means of
a confocal scanning laser ophthalmoscope. Administration6 Journal of Ophthalmology
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Figure 4: Light microscopic view of two pairs of optic nerves (toluidine blue stain). Optic nerves subjected to endothelin-1 during 8 weeks
((a) and (c)) showed a loss of myelin (dark areas) and a gliosis of the prelaminar portion of the optic nerve compared to the contralateral
eyes ((b) and (d)). Arrows point to myelinated nerve ﬁbers in the control eyes ((b) and (d)). Figure adapted from Orgul et al. [51].
of endothelin-1 to the anterior optic nerve region induced
a signiﬁcant decrease in local blood ﬂow of approximately
38% compared to the contralateral eye. Multivariate analysis
disclosed a small, but statistically signiﬁcant change in optic
nerve morphology, as measured with a confocal scanning
laser ophthalmoscope, after 8 weeks of local administration
of endothelin-1, compared to the control eye. These changes
were consistent with an optic nerve cupping and a decrease
in optic nerve rim volume. Histologic analysis showed loss
of myelin and gliosis of the prelaminar portion of the
optic nerve in optic nerves subjected to endothelin-1 for 8
weeks (Figure 4). Blood ﬂow and morphologic changes were
independent of changes in intraocular pressure.
In healthy young humans, the circulating levels of
endothelin are low [56]. In pathologic conditions such
as an ischemic cerebrovascular insult, the plasma level of
endothelin-1 has been reported to be elevated [57]. Emre
and coworkers [52] found increased plasma level of ET-1
in primary open-angle glaucoma patients with progressive
damage when compared with primary open-angle glaucoma
patients with stable visual ﬁelds, this diﬀerence was inde-
pendent of sex, age, and mean blood pressure. Furthermore,
they found that values obtained among patients with a stable
visual ﬁeld were above the reference values established in
their laboratory (Figure 5). A possible explanation would be
that ET-1 may contribute to the initiation of the damaging
processes in glaucoma, but then remain increased as a
consequence of the damage.
Endothelin may also directly regulate the blood ﬂow
within the optic nerve [58]. The ocular circulation is
particularly sensitive to changes in local ET-1 concentration,
even at doses that do not aﬀect the systemic haemodynamics
or ﬂow velocity in the ophthalmic artery [59]. In some
individuals with primary open-angle glaucoma, higher-than
normal plasma and asqueous humor concentrations of ET-
1h a v eb e e no b s e r v e d[ 60–63]. This high concentration
of ET-1 has been associated with reduced blood ﬂow in
the posterior ciliary arteries that supply the optic nerve
vasculature. Peripheral vascular response to ET-1 is also
altered in some individuals with glaucoma. Intravitreal
injections of ET-1 into the rabbit eye produce marked eﬀects
on the anterior ciliary circulation, as well as constriction
of the retinal vasculature. With ET-1 administration to the
retrobulbar perineural space, localized constriction in the
posterior ciliary arterial circulation has been produced in
both the rabbit and primate eye [64].
7.Endethelin-1andRetinalDetachment
ET-1 is found in the photoreceptor inner segments of the
human retina where it may play a role in neuromodulation
or neurotransmission [65, 66].Journal of Ophthalmology 7
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Figure 5: Plasma concentration of ET-1 in patients with glaucoma
with and without visual ﬁeld progression (triangle = mean; box =
standarderrorodthemean;whiskers =standarddeviation).Plasma
levels of ET-1 at the end of the observation period were signiﬁcantly
higher in patients with progressive damage (3.47 (0.75)pg/ml;
range 2.34–5.17pg/ ml) compared with those with stable (2.60
(SD 0.54)pg/ml; range 1.91–3.45pg/ml) visual ﬁelds (ANOVA:
F(1,29) = 13.94281; P = .0008). This diﬀerence was still signiﬁcant
after controlling for the interaction of sex and including age and
MBP as covariates into the model (ANCOVA: F(1,25) = 14.95;
P = .0007). Sex had a borderline signiﬁcant eﬀect (ANCOVA:
F(1,25) = 4.25; P = .0497), but the interaction between sex and
disease progression was not signiﬁcant (ANCOVA: F(1,25) = 1.84;
P = .19). Figure adapted from Emre et al. [52].
ET-1 immunoreactivity is present on the cell body of
the astrocytes and both ET-1 mRNA and ET-1 immunore-
activity have been found in the retinal pigment epithelium
(RPE) cells. Elevated subretinal ﬂuid (SRF) and vitreous
immunoreactive ET-1 (IR-ET-1) [67] levels were associated
with RD (retinal detachment) and proliferative vitreoreti-
nopathy (PVR) [68].
IR- ET-1 was localized in the cellular and stromal
components of PVR membranes where, ETA and ETB
receptor expression has also been demonstrated.
The signiﬁcant correlation found between SRF-IR-ET-1
and plasma IR-ET1 suggests that intraocular IR-ET1 derives
in part from systemic circulation, but the slope of the
correlation, always greater for the PVR group, is consistent
with enhanced access of plasma proteins in the eye due
to a disruption of the blood-ocular barrier. The increased
diﬀerence of SRF- plasma IR-ET1 in the PVR group may also
suggest a local ET-1 production in PVR.
Endothelin could play a role in photoreceptor synaptic
transmission, and this would require thight control of
the endothelin extracellular concentration. Modulation of
synaptic transmission might aﬀect photoreceptor survival,
perhaps by regulating glutamate release [69].
RPE and glial cells are the main contributors to mem-
braneformationandcontractioninPVR.Thepossibilitythat
RPE plays a role in endothelin-mediated photoreceptor sur-
vival cannot be excluded because this retinal layer contains
ET-1, prepro-ET-1, and ETA immunoreactivities [70].
ET-1 may also act as growth factor for astrocytes, in-
ducing DNA synthesis and proliferation [71]. Astrocytic
proliferation together with an excessive secretion of ET-
1 has been reported in cerebral focal ischemia in vivo
[72]. Sasaki et al. [73] demonstrated that ET-1 speciﬁcally
stimulated the eﬄux of glutamate via ETB receptors from
cultured rat astrocytes, suggesting that ET-1 may esacerbate
neurodegeneration. Infusion of ETB selective antagonists
attenuates the increase in astrocytes after injury of the
brain cortex, indicating that induction of reactive astrocytes
depends on the activation of ETB receptors [74]. Reactive
gliosis has been suggested as a clinically signiﬁcant limiting
factor in the recovery of vision after RD. Excess of ET-
1 released by injured glial cells can be compensated by
scavenging ETB receptors, [75] and it has been suggested
that blockade of these receptors after central nervous system
injurymightmodulateglialscarformation,providingamore
permissive substrate for neural survival and regeneration
[76]. Rold´ an-Pallar´ es et al. [77] investigated the relationship
between visual acuity (VA) and SRF-IR-ET1 levels in RD.
They concluded that VA was inversely correlated with SRF-
IR-ET1 levels. Nevertheless, the highest negative correlation
between postoperative VA and VA diﬀerence and the SRF-
IR-ET1 levels was found in the group with proliferative
complication of retinal detachment (PVR). These ﬁndings
support the idea of performing a primary vitrectomy at
early stages of pathology in RD to eliminate the intraocular
peptide and perhaps associate a pharmacologic therapy in
RD, more importantly in PVR.
ET-1 can modulate anterograde fast axonal transport,
which is essential for maintaining synaptic function and
neuronal survival [78].
Recently experimental evidence that stimulation of
endothelinergic receptors may modulate photoreceptor sur-
vival and glial activation has been provided [79].
8. Conclusion
Antiendothelin monoclonal antibodies as well as recep-
tor antagonists BQ-123 (ETA selective, peptidic) and Ro
46-2005 (nonselective, nonpeptidic) have been repeatedly
shown to ameliorate ischemic and cyclosporine-induced
acute renal failure. Chronic administration of FR 139317,
another ETA selective antagonist, was eﬀective in preventing
progressive proliferative renal disease and associated hyper-
tension in a rat model of chronic glomerulonephropathy
induced by surgical renal mass reduction. The blockade
of endothelin action by neutralizing antibodies or BQ-
123 has been shown to reduce the extent of experimental
acute myocardial infarction in rat, rabbit, and dog. The
peptidic ETA selective antagonist BQ-485 is eﬀective in
preventing delayed cerebrovascular spasm in a dog model of
subarachnoid hemorrhage. In a similar model in the rabbit,
the nonpeptidic antagonist Ro-47-0203 reverses delayed
vasospasm. Furthermore, endothelin receptor antagonists
lower basal blood pressure in spontaneously hypertensive
and spontaneously hypertensive strokeprone strains of rats
as well as in sodium-depleted squirrel monkeys, suggesting a
possible role for endothelins in maintaining blood pressure8 Journal of Ophthalmology
control under certain conditions and in the development
of genetically determined hypertension. The antagonist not
only reduces blood pressure but also prevents secondary
renal disease observed in DOCA/salt-treated, spontaneously
hypertensive rats with malignant hypertension.
ECE (endothelin-converting enzyme) represents another
target for pharmacological intervention on the endothelin
system because ECE appears to be a metalloprotease that
has a strict substrate speciﬁcity. A selective inhibitor for
the enzyme can presumably inhibit the production of active
endothelins in a highly fast manner. Unfortunately, this
avenue of research has been severely hampered in the
past because of the elusive molecular nature of ECE itself.
However, now that ECE has been apparently puriﬁed to
near-homogeneity, this major component of the endothelin
system should soon be revealed at the molecular level.
Endothelin-1 itself could be the target molecule of new
therapeutic drugs. In a recent study, Scorza et al. [80]
analyzed the inﬂuence of aminaphtone, a 4-aminobenzoic
acid derivative clinically used for the treatment of capillary
disorders, on ET-1 protein production, pre pro endothelin
(PPET-1) gene expression and ECE activity in human
ECV304 cells after incubation with physiological concentra-
tions of interleukin-1β (IL-1β). ECV304 cells originate from
endothelial cells of human umbilical vein by spontaneous
transformation and have been widely used for in vitro
studies of the endothelium and ET-1 pathways, since they
are able to produce ET-1 and express the mRNA and the
α-isoform of ECE. They demonstrated that addition of
diﬀerent concentrations of aminaphtone to ECV304 cells
reduces production of ET-1 and downregulates PPET-1 gene
expression in a concentration-dependent manner. More-
over they observed that aminaphtone at a concentration
of 6μg/mL, which roughly represents the peak plasma
concentration reached after oral administration of 75mg
of the drug, reverts production of ET-1 to baseline values
[80]. This may encourage clinical trials on the eﬃcacy of
this molecule in the downregulation of ET-1 levels in eye
disorders. Development in the near future of nonpeptidic
receptor antagonists with even higher potency and speciﬁc
ECE inhibitors shoud further facilitate the understanding of
thebiologicalroleofendothelinsinhealthanddisease.Those
new biological insights should provide renewed promise
for the progress toward this novel target for therapeutic
intervention, which may include ocular diseases for which
no eﬀective drug treatment is currently available.
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